ReviewCell death & disease2015
Multiple sclerosis: getting personal with induced pluripotent stem cells.
Review in Cell death & disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- From Molecules to Models: miRNAs and Advanced Human Platforms of Neurodegeneration and Repair in Multiple Sclerosis.International journal of molecular sciences · 2025Review
- Animal models in neuroscience with alternative approaches: Evolutionary, biomedical, and ethical perspectives.Animal models and experimental medicine · 2024Review
- Changes of Target Essential Trace Elements in Multiple Sclerosis: A Systematic Review and Meta-Analysis.Biomedicines · 2024Review
- MS-Driven Metabolic Alterations Are Recapitulated in iPSC-Derived Astrocytes.Annals of neurology · 2022Article
- Review
- The Post-GWAS Era: How to Validate the Contribution of Gene Variants in Lupus.Current rheumatology reports · 2019Review
- Experimental autoimmune encephalomyelitis in the common marmoset: a translationally relevant model for the cause and course of multiple sclerosis.Primate biology · 2019Review
- Neural Stem Cell-Based Regenerative Approaches for the Treatment of Multiple Sclerosis.Molecular neurobiology · 2018Review
- Viruses and Multiple Sclerosis: From Mechanisms and Pathways to Translational Research Opportunities.Molecular neurobiology · 2017Review
- Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response.Stem cell reports · 2017Article
- Advances in Monitoring Cell-Based Therapies with Magnetic Resonance Imaging: Future Perspectives.International journal of molecular sciences · 2017Review
- Differential regulated microRNA by wild type and mutant p53 in induced pluripotent stem cells.Cell death & disease · 2016Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Human induced pluripotent stem (iPS) cells can be derived from lineage-restricted cells and represent an important tool to develop novel patient-specific cell therapies and research models for inherited and acquired diseases. Recently, patient-derived iPS cells, containing donor genetic background, have offered a breakthrough approach to study human genetics of neurodegenerative diseases. By offering an unlimited source of patient-specific disease-relevant cells, iPS cells hold great promise for understanding disease mechanisms, identifying molecular targets and developing phenotypic screens for drug discovery. This review will discuss the potential impact of using iPS cell-derived models in multiple sclerosis (MS) research and highlight some of the current challenges and prospective for generating novel therapeutic treatments for MS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.